YIDU TECH (02158) surged over 6%, and as of press time, the stock was up 6.27% to HK$7.12, with trading volume reaching HK$112 million.

On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drops Phase III clinical research project, with a total project value of approximately RMB 55.82 million.

Additionally, the "First Medical Artificial Intelligence Conference and Healthcare Industry AI Application and Industrial Development Exhibition," hosted by the Chinese Journal of Health Informatics, was recently held in Jinan. At the conference's "AI-Driven Medical Quality Improvement" forum, Dr. Li Linfeng, Vice President of Technology Innovation and AI Architect at YIDU TECH, introduced that the company has built a "Doctor Copilot" that deeply integrates with clinical workflows, using "big data + YIDU's vertical domain large model" as its technical foundation.

Currently, the Doctor Copilot has been implemented in multiple hospitals, effectively improving diagnostic and treatment efficiency and quality, helping clinical practice achieve intelligent and standardized upgrades.